Microalbuminuria in the course of familial Mediterranean fever

Sir,

In their interesting paper, Lobato et al. [1] studied the importance of microalbuminuria as a predictor of symptomatic disease and clinical nephropathy in familial transthretin related amyloidosis. They demonstrated that microalbuminuria represents a first stage of clinical amyloid nephropathy and that it could be premonitory of neuropathy. They recommend the systematic and regular search for urinary albumin excretion in symptomatic gene carriers and patients, instead of renal biopsy, as a non-invasive method for estimating the progression of amyloidosis.

Previously, it has been shown that in cases of essential hypertension and diabetic nephropathy, early renal glomerular damage can be detected by microalbuminuria [2]. Saatci et al. [3] previously showed increased urinary ß2-microglobulin excretion and microalbuminuria during familial Mediterranean fever (FMF) attacks. FMF is characterized by recurrent fever and serositis. The most important complication of the disease is AA amyloidosis. Proteinuria and renal failure may complicate the clinical course. We have measured the microalbuminuria and urinary glycosaminoglycan (GAG) levels as predictors of amyloidosis in patients with FMF in an attack-free period. We found that mean urinary GAG levels of the patients with FMF secondary amyloidosis were lower than those of FMF patients without amyloidosis [4]. When we examined the duration of disease in the FMF group without amyloidosis, we saw that median GAG levels were significantly lower in patients having the disease for >10 years compared with those having the disease for <3 years. Also, microalbuminuria levels tended to increase with the duration of the disease. In FMF patients with low GAG levels, colchicine dose was increased and urinary GAG and microalbuminuria levels were re-examined after 2 weeks. In these patients, urinary GAG levels increased significantly with increments in the colchicine dose. Microalbuminuria decreased along with the increase in urinary GAG when colchicine dose was increased.

These results suggest that urinary GAG and microalbuminuria may be predictors of amyloidosis in FMF patients. We also suggest that effective colchicine dosing may be monitored by following urinary GAG excretion and microalbuminuria. Our results are in agreement with the recommendation by Lobato et al.

Conflict of interest statement. None declared.

Esra Baskin and Umit Saatci

Pediatric Nephrology Baskent University Ankara Turkey Email: esrabaskin{at}hotmail.com

References

  1. Lobato L, Beirao I, Silva M et al. Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy. Nephrol Dial Transplant 2003; 18: 532–538[Abstract/Free Full Text]
  2. Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension: significance, pathophysiology and therapeutic implications. Am J Kidney Dis 1999; 34: 973–995[ISI][Medline]
  3. Saatci U, Ozdemir S, Ozen S, Bakkaloglu A. Serum concentration and urinary excretion of ß2-microglobulin and microalbuminuria in familial Mediterranean fever. Arch Dis Child 1994; 70: 27–29[Abstract]
  4. Baskin E, Saatci U, Ciliv G et al. Urinary glycosaminoglycans in the course of familial Mediterranean fever. Eur J Pediatr 2003; 162: 305–308[ISI][Medline]




This Article
Extract
FREE Full Text (PDF)
Alert me when this article is cited
Alert me if a correction is posted
Services
Email this article to a friend
Similar articles in this journal
Similar articles in ISI Web of Science
Similar articles in PubMed
Alert me to new issues of the journal
Add to My Personal Archive
Download to citation manager
Disclaimer
Request Permissions
Google Scholar
Articles by Baskin, E.
Articles by Saatci, U.
PubMed
PubMed Citation
Articles by Baskin, E.
Articles by Saatci, U.